Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bonraybio Co. Ltd. (6955:TWSE), powered by AI.
Bonraybio Co. Ltd. is currently trading at $147.50. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bonraybio Co. Ltd. on Alpha Lenz.
Bonraybio Co. Ltd.'s P/E ratio is 113.2.
“Bonraybio Co. Ltd. trades at a P/E of 113.2 (premium valuation) with solid ROE of 9.7%.”
Ask for details →Bonraybio Co. Ltd. is a prominent biotechnology company primarily engaged in the development and commercialization of advanced diagnostic solutions. Its core focus is on the creation of sophisticated diagnostic tests and systems that address a variety of health conditions. This company operates within the healthcare and life sciences sector, often at the forefront of innovative diagnostic research that aids in early detection and management of diseases. Bonraybio’s solutions contribute significantly to areas like oncology, infectious diseases, and personalized medicine, enabling more precise and timely patient care. By leveraging cutting-edge technologies, Bonraybio plays a crucial role in enhancing diagnostic accuracy and efficiency, ultimately contributing to improved healthcare outcomes. The company's presence in the bio-diagnostics market underscores its commitment to advancing scientific knowledge and supporting the global healthcare infrastructure through reliable and accessible diagnostic tools.
“Bonraybio Co. Ltd. trades at a P/E of 113.2 (premium valuation) with solid ROE of 9.7%.”
Ask for details →Bonraybio Co. Ltd. (ticker: 6955) is a company listed on TWSE in the Healthcare sector (Medical Devices). Market cap is $2.9B.
The current price is 147.5 with a P/E ratio of 113.15x and P/B of 10.45x.
ROE is 9.68% and operating margin is 13.37%. Annual revenue is $160M.